PortalPublikationenSimultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localizati...

Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer

Standard

Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. / Eiber, Matthias; Weirich, Gregor; Holzapfel, Konstantin; Souvatzoglou, Michael; Haller, Bernhard; Rauscher, Isabel; Beer, Ambros J; Wester, Hans-Jürgen; Gschwend, Juergen; Schwaiger, Markus; Maurer, Tobias.

in: EUR UROL, Jahrgang 70, Nr. 5, 11.2016, S. 829-836.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung

Harvard

Eiber, M, Weirich, G, Holzapfel, K, Souvatzoglou, M, Haller, B, Rauscher, I, Beer, AJ, Wester, H-J, Gschwend, J, Schwaiger, M & Maurer, T 2016, 'Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer', EUR UROL, Jg. 70, Nr. 5, S. 829-836. https://doi.org/10.1016/j.eururo.2015.12.053

APA

Eiber, M., Weirich, G., Holzapfel, K., Souvatzoglou, M., Haller, B., Rauscher, I., Beer, A. J., Wester, H-J., Gschwend, J., Schwaiger, M., & Maurer, T. (2016). Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. EUR UROL, 70(5), 829-836. https://doi.org/10.1016/j.eururo.2015.12.053

Vancouver

Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I et al. Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. EUR UROL. 2016 Nov;70(5):829-836. https://doi.org/10.1016/j.eururo.2015.12.053

Bibtex

@article{a6954905e6e74a90a245db91f759fb38,
title = "Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer",
abstract = "BACKGROUND: Ligands of the prostate-specific membrane antigen (PSMA) show promising results in positron emission tomography (PET) imaging of prostate cancer (PCa).OBJECTIVE: To compare the diagnostic performance of simultaneous gallium 68 (68Ga)-PSMA HBED-CC PET/magnetic resonance imaging (MRI) for localization of primary PCa with multiparametric magnetic resonance imaging (mpMRI) and PET alone.DESIGN, SETTING, AND PARTICIPANTS: We performed 68Ga-PSMA HBED-CC PET/MRI in 66 men with biopsy-proven PCa.INTERVENTION: PET, mpMRI, and combined 68Ga-PSMA HBED-CC PET/MRI were independently evaluated using Prostate Imaging Reporting and Data System criteria or a 5-point Likert scale.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The prostate was divided into sextants for histopathology and coregistered with imaging. Diagnostic performance for localization of malignancy was calculated based on receiver operating characteristics analysis for each modality. Regional quantitative PET tracer uptake was recorded; uptake ratio was defined as the ratio of malignant to nonmalignant prostate tissue.RESULTS AND LIMITATIONS: A total of 53 of 66 patients were eligible for analysis. mpMRI, PET, and PET/MRI detected cancer in 66% (35 of 53), 92% (49 of 53), and 98% (52 of 53) of the patients, respectively. Overall, 202 of 318 sextants (63.5%) contained cancer at pathologic examination. Simultaneous PET/MRI statistically outperformed mpMRI (area under the curve [AUC]: 0.88 vs 0.73; p<0.001) and PET imaging (AUC: 0.88 vs 0.83; p=0.002) for localization of PCa. Compared with mpMRI, PET imaging was more accurate (AUC: 0.83 vs 0.73; p=0.003). PET provided a high uptake ratio between malignant versus nonmalignant tissue (5.02 [range: 0.89-29.8]), but no significant correlation was observed between quantitative PET parameters and Gleason score or prostate-specific antigen value.CONCLUSIONS: Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves diagnostic accuracy for PCa localization both compared with mpMRI and with PET imaging alone. Further prospective studies are warranted to evaluate its potential (eg, for biopsy guidance).PATIENT SUMMARY: We examined gallium 68 (68Ga)-prostate-specific membrane antigen (PSMA) HBED-CC positron emission tomography/magnetic resonance imaging (PET/MRI) for primary prostate cancer (PCa) and compared it with multiparametric MRI and PET alone. Our results indicate a higher diagnostic accuracy for 68Ga-PSMA HBED-CC PET/MRI that may help localize PCa.",
keywords = "Aged, Biopsy, Comparative Effectiveness Research, Dimensional Measurement Accuracy, Gallium Radioisotopes, Germany, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Positron-Emission Tomography, Prostate, Prostate-Specific Antigen, Prostatic Neoplasms, ROC Curve, Radiopharmaceuticals, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't",
author = "Matthias Eiber and Gregor Weirich and Konstantin Holzapfel and Michael Souvatzoglou and Bernhard Haller and Isabel Rauscher and Beer, {Ambros J} and Hans-J{\"u}rgen Wester and Juergen Gschwend and Markus Schwaiger and Tobias Maurer",
note = "Copyright {\textcopyright} 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2016",
month = nov,
doi = "10.1016/j.eururo.2015.12.053",
language = "English",
volume = "70",
pages = "829--836",
journal = "EUR UROL",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer

AU - Eiber, Matthias

AU - Weirich, Gregor

AU - Holzapfel, Konstantin

AU - Souvatzoglou, Michael

AU - Haller, Bernhard

AU - Rauscher, Isabel

AU - Beer, Ambros J

AU - Wester, Hans-Jürgen

AU - Gschwend, Juergen

AU - Schwaiger, Markus

AU - Maurer, Tobias

N1 - Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2016/11

Y1 - 2016/11

N2 - BACKGROUND: Ligands of the prostate-specific membrane antigen (PSMA) show promising results in positron emission tomography (PET) imaging of prostate cancer (PCa).OBJECTIVE: To compare the diagnostic performance of simultaneous gallium 68 (68Ga)-PSMA HBED-CC PET/magnetic resonance imaging (MRI) for localization of primary PCa with multiparametric magnetic resonance imaging (mpMRI) and PET alone.DESIGN, SETTING, AND PARTICIPANTS: We performed 68Ga-PSMA HBED-CC PET/MRI in 66 men with biopsy-proven PCa.INTERVENTION: PET, mpMRI, and combined 68Ga-PSMA HBED-CC PET/MRI were independently evaluated using Prostate Imaging Reporting and Data System criteria or a 5-point Likert scale.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The prostate was divided into sextants for histopathology and coregistered with imaging. Diagnostic performance for localization of malignancy was calculated based on receiver operating characteristics analysis for each modality. Regional quantitative PET tracer uptake was recorded; uptake ratio was defined as the ratio of malignant to nonmalignant prostate tissue.RESULTS AND LIMITATIONS: A total of 53 of 66 patients were eligible for analysis. mpMRI, PET, and PET/MRI detected cancer in 66% (35 of 53), 92% (49 of 53), and 98% (52 of 53) of the patients, respectively. Overall, 202 of 318 sextants (63.5%) contained cancer at pathologic examination. Simultaneous PET/MRI statistically outperformed mpMRI (area under the curve [AUC]: 0.88 vs 0.73; p<0.001) and PET imaging (AUC: 0.88 vs 0.83; p=0.002) for localization of PCa. Compared with mpMRI, PET imaging was more accurate (AUC: 0.83 vs 0.73; p=0.003). PET provided a high uptake ratio between malignant versus nonmalignant tissue (5.02 [range: 0.89-29.8]), but no significant correlation was observed between quantitative PET parameters and Gleason score or prostate-specific antigen value.CONCLUSIONS: Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves diagnostic accuracy for PCa localization both compared with mpMRI and with PET imaging alone. Further prospective studies are warranted to evaluate its potential (eg, for biopsy guidance).PATIENT SUMMARY: We examined gallium 68 (68Ga)-prostate-specific membrane antigen (PSMA) HBED-CC positron emission tomography/magnetic resonance imaging (PET/MRI) for primary prostate cancer (PCa) and compared it with multiparametric MRI and PET alone. Our results indicate a higher diagnostic accuracy for 68Ga-PSMA HBED-CC PET/MRI that may help localize PCa.

AB - BACKGROUND: Ligands of the prostate-specific membrane antigen (PSMA) show promising results in positron emission tomography (PET) imaging of prostate cancer (PCa).OBJECTIVE: To compare the diagnostic performance of simultaneous gallium 68 (68Ga)-PSMA HBED-CC PET/magnetic resonance imaging (MRI) for localization of primary PCa with multiparametric magnetic resonance imaging (mpMRI) and PET alone.DESIGN, SETTING, AND PARTICIPANTS: We performed 68Ga-PSMA HBED-CC PET/MRI in 66 men with biopsy-proven PCa.INTERVENTION: PET, mpMRI, and combined 68Ga-PSMA HBED-CC PET/MRI were independently evaluated using Prostate Imaging Reporting and Data System criteria or a 5-point Likert scale.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The prostate was divided into sextants for histopathology and coregistered with imaging. Diagnostic performance for localization of malignancy was calculated based on receiver operating characteristics analysis for each modality. Regional quantitative PET tracer uptake was recorded; uptake ratio was defined as the ratio of malignant to nonmalignant prostate tissue.RESULTS AND LIMITATIONS: A total of 53 of 66 patients were eligible for analysis. mpMRI, PET, and PET/MRI detected cancer in 66% (35 of 53), 92% (49 of 53), and 98% (52 of 53) of the patients, respectively. Overall, 202 of 318 sextants (63.5%) contained cancer at pathologic examination. Simultaneous PET/MRI statistically outperformed mpMRI (area under the curve [AUC]: 0.88 vs 0.73; p<0.001) and PET imaging (AUC: 0.88 vs 0.83; p=0.002) for localization of PCa. Compared with mpMRI, PET imaging was more accurate (AUC: 0.83 vs 0.73; p=0.003). PET provided a high uptake ratio between malignant versus nonmalignant tissue (5.02 [range: 0.89-29.8]), but no significant correlation was observed between quantitative PET parameters and Gleason score or prostate-specific antigen value.CONCLUSIONS: Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves diagnostic accuracy for PCa localization both compared with mpMRI and with PET imaging alone. Further prospective studies are warranted to evaluate its potential (eg, for biopsy guidance).PATIENT SUMMARY: We examined gallium 68 (68Ga)-prostate-specific membrane antigen (PSMA) HBED-CC positron emission tomography/magnetic resonance imaging (PET/MRI) for primary prostate cancer (PCa) and compared it with multiparametric MRI and PET alone. Our results indicate a higher diagnostic accuracy for 68Ga-PSMA HBED-CC PET/MRI that may help localize PCa.

KW - Aged

KW - Biopsy

KW - Comparative Effectiveness Research

KW - Dimensional Measurement Accuracy

KW - Gallium Radioisotopes

KW - Germany

KW - Humans

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Positron-Emission Tomography

KW - Prostate

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

KW - ROC Curve

KW - Radiopharmaceuticals

KW - Comparative Study

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1016/j.eururo.2015.12.053

DO - 10.1016/j.eururo.2015.12.053

M3 - SCORING: Journal article

C2 - 26795686

VL - 70

SP - 829

EP - 836

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 5

ER -